Biotech ETFs: Orexigen Hit By Regulatory Hammer
June 03, 2011 at 15:47 PM EDT
Biotech sector and related exchange traded funds (ETFs) trade lower as one drug maker garners notoriety after regulatory hurdles puts a hold on the advancement of an anticipated diet pill. iShares Nasdaq Biotechnology (NYSEArca: IBB) is down 0.83%. First Trust Amex Biotech Index Fund (NYSEAca:...